A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of A beta(38), A beta(40), and A beta(42) in Cerebrospinal Fluid of Alzheimer%26apos;s Disease Patients and Healthy Controls

作者：Pannee Josef^*; Portelius Erik; Oppermann Madalina; Atkins Alan; Hornshaw Martin; Zegers Ingrid; Hojrup Peter; Minthon Lennart; Hansson Oskar; Zetterberg Henrik; Blennow Kaj; Gobom Johan

来源：Journal of Alzheimer's Disease, 2013, 33(4): 1021-1032.

DOI：10.3233/JAD-2012-121471

• Alzheimer%26apos
• s disease
• amyloid-beta
• cerebrospinal fluid
• mass spectrometry
• selected reaction monitoring

Cerebrospinal fluid (CSF) biomarkers for Alzheimer%26apos;s disease (AD) are increasingly used in research centers, clinical trials, and clinical settings. However, their broad-scale use is hampered by lack of standardization across analytical platforms and by interference from binding of amyloid-beta(A beta) to matrix proteins as well as self-aggregation. Here, we report on a matrix effect-resistant method for the measurement of the AD-associated 42 amino acid species of A beta(A beta(42)), together with A beta(40) and A beta(38) in human CSF based on mass spectrometric quantification using selected reaction monitoring (SRM). Samples were prepared by solid-phase extraction and quantification was performed using stable-isotope labeled A beta peptides as internal standards. The diagnostic performance of the method was evaluated on two independent clinical materials with research volunteers who were cognitively normal and AD patients with mild to moderate dementia. Analytical characteristics of the method include a lower limit of quantification of 62.5 pg/mL for A beta(42) and coefficients of variations below 10%. In a pilot study on AD patients and controls, we verified disease-association with decreased levels of A beta(42) similar to that obtained by ELISA and even better separation was obtained using the A beta(42)/A beta(40) ratio. The developed assay is sensitive and is not influenced by matrix effects, enabling absolute quantification of A beta(42), A beta(40), and A beta(38) in CSF, while it retains the ability to distinguish AD patients from controls. We suggest this SRM-based method for A beta peptide quantification in human CSF valuable for clinical research and trials.

• 出版日期2013